

## ASX ANNOUNCEMENT

### ASX Appendix 4C Quarterly Cash Flow Report for the quarter ended 30 September 2013

**Sydney, 31 October 2013:** Benitec Biopharma Limited (ASX: BLT) today lodged with ASX the quarterly cash flow report Appendix 4C for period ended 30 September 2013.

Benitec held \$6.2 million in cash at 30 September 2013, compared to \$1.5 million at 30 June 2013. Net operating cash flow for the quarter was (\$5.0) million, and included scientific and business development expenditure of \$4.1 million.

Benitec announced on 3 June 2013 that it had committed to moving Tribetarna™, its non-small cell lung cancer therapeutic, into clinical development in 2014. The Company is using European-based clinical research organisation Clinical Trials Group (CTGCRO) to manage both the initial clinical development and trials, and Benitec made pre-payments during the quarter in order to secure favourable commercial terms with CTGCRO for the conduct of the trials.

Accordingly, scientific and business development expenditure for the period includes the CTGCRO fee, together with \$0.6 million expenditure on advancing the Company's US-based hepatitis C (HCV) clinical trial and costs on other pipeline programs.

Net proceeds during the quarter from share issues totalled \$9.6 million, and included \$2.8 million from the Share Purchase Plan.

**For more information please contact:** Greg West | Company Secretary  
Phone: +61 (02) 9555 6986 | [gwest@benitec.com](mailto:gwest@benitec.com) | [www.benitec.com](http://www.benitec.com)

**About Benitec Biopharma Limited:** Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at [www.benitec.com](http://www.benitec.com)